vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Grand Canyon Education, Inc. (LOPE). Click either name above to swap in a different company.
Grand Canyon Education, Inc. is the larger business by last-quarter revenue ($308.1M vs $281.3M, roughly 1.1× Guardant Health, Inc.). Grand Canyon Education, Inc. runs the higher net margin — 28.1% vs -45.7%, a 73.8% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 5.3%). Grand Canyon Education, Inc. produced more free cash flow last quarter ($122.9M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 5.9%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Grand Canyon Education, Inc. (GCE) is an American for-profit corporation that provides services to universities, specializing in program development, online education, and operational support. Formerly affiliated with Grand Canyon University (GCU), a Christian university in Arizona, GCE became a separate publicly traded company in 2008.
GH vs LOPE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $308.1M |
| Net Profit | $-128.5M | $86.7M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 35.1% |
| Net Margin | -45.7% | 28.1% |
| Revenue YoY | 39.4% | 5.3% |
| Net Profit YoY | -15.8% | 5.9% |
| EPS (diluted) | $-1.01 | $3.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $308.1M | ||
| Q3 25 | $265.2M | $261.1M | ||
| Q2 25 | $232.1M | $247.5M | ||
| Q1 25 | $203.5M | $289.3M | ||
| Q4 24 | $201.8M | $292.6M | ||
| Q3 24 | $191.5M | $238.3M | ||
| Q2 24 | $177.2M | $227.5M | ||
| Q1 24 | $168.5M | $274.7M |
| Q4 25 | $-128.5M | $86.7M | ||
| Q3 25 | $-92.7M | $16.3M | ||
| Q2 25 | $-99.9M | $41.5M | ||
| Q1 25 | $-95.2M | $71.6M | ||
| Q4 24 | $-111.0M | $81.9M | ||
| Q3 24 | $-107.8M | $41.5M | ||
| Q2 24 | $-102.6M | $34.9M | ||
| Q1 24 | $-115.0M | $68.0M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 35.1% | ||
| Q3 25 | -37.3% | 6.9% | ||
| Q2 25 | -45.9% | 20.9% | ||
| Q1 25 | -54.6% | 30.4% | ||
| Q4 24 | -62.4% | 34.2% | ||
| Q3 24 | -61.3% | 20.2% | ||
| Q2 24 | -56.8% | 18.8% | ||
| Q1 24 | -59.2% | 30.8% |
| Q4 25 | -45.7% | 28.1% | ||
| Q3 25 | -35.0% | 6.2% | ||
| Q2 25 | -43.0% | 16.8% | ||
| Q1 25 | -46.8% | 24.8% | ||
| Q4 24 | -55.0% | 28.0% | ||
| Q3 24 | -56.3% | 17.4% | ||
| Q2 24 | -57.9% | 15.3% | ||
| Q1 24 | -68.2% | 24.8% |
| Q4 25 | $-1.01 | $3.13 | ||
| Q3 25 | $-0.74 | $0.58 | ||
| Q2 25 | $-0.80 | $1.48 | ||
| Q1 25 | $-0.77 | $2.52 | ||
| Q4 24 | $-0.90 | $2.83 | ||
| Q3 24 | $-0.88 | $1.42 | ||
| Q2 24 | $-0.84 | $1.19 | ||
| Q1 24 | $-0.94 | $2.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $111.8M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $746.9M |
| Total Assets | $2.0B | $992.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $111.8M | ||
| Q3 25 | $580.0M | $97.3M | ||
| Q2 25 | $629.1M | $192.3M | ||
| Q1 25 | $698.6M | $144.5M | ||
| Q4 24 | $525.5M | $324.6M | ||
| Q3 24 | $585.0M | $263.6M | ||
| Q2 24 | $933.7M | $241.3M | ||
| Q1 24 | $1.0B | $196.2M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $746.9M | ||
| Q3 25 | $-354.5M | $758.0M | ||
| Q2 25 | $-305.5M | $778.0M | ||
| Q1 25 | $-250.8M | $780.7M | ||
| Q4 24 | $-139.6M | $783.9M | ||
| Q3 24 | $-60.1M | $764.1M | ||
| Q2 24 | $-1.6M | $759.2M | ||
| Q1 24 | $68.3M | $759.4M |
| Q4 25 | $2.0B | $992.3M | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $1.3B | $1.0B | ||
| Q1 25 | $1.3B | $1.0B | ||
| Q4 24 | $1.5B | $1.0B | ||
| Q3 24 | $1.5B | $992.9M | ||
| Q2 24 | $1.6B | $992.7M | ||
| Q1 24 | $1.7B | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $130.5M |
| Free Cash FlowOCF − Capex | $-54.2M | $122.9M |
| FCF MarginFCF / Revenue | -19.3% | 39.9% |
| Capex IntensityCapex / Revenue | 9.9% | 2.5% |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $238.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $130.5M | ||
| Q3 25 | $-35.4M | $-48.6M | ||
| Q2 25 | $-60.3M | $124.0M | ||
| Q1 25 | $-62.7M | $67.6M | ||
| Q4 24 | $-64.5M | $135.8M | ||
| Q3 24 | $-51.1M | $-29.4M | ||
| Q2 24 | $-94.0M | $98.6M | ||
| Q1 24 | $-30.3M | $85.0M |
| Q4 25 | $-54.2M | $122.9M | ||
| Q3 25 | $-45.8M | $-58.3M | ||
| Q2 25 | $-65.9M | $115.4M | ||
| Q1 25 | $-67.1M | $58.7M | ||
| Q4 24 | $-83.4M | $126.1M | ||
| Q3 24 | $-55.3M | $-39.0M | ||
| Q2 24 | $-99.1M | $89.6M | ||
| Q1 24 | $-37.2M | $76.0M |
| Q4 25 | -19.3% | 39.9% | ||
| Q3 25 | -17.3% | -22.3% | ||
| Q2 25 | -28.4% | 46.6% | ||
| Q1 25 | -33.0% | 20.3% | ||
| Q4 24 | -41.3% | 43.1% | ||
| Q3 24 | -28.9% | -16.3% | ||
| Q2 24 | -55.9% | 39.4% | ||
| Q1 24 | -22.1% | 27.7% |
| Q4 25 | 9.9% | 2.5% | ||
| Q3 25 | 3.9% | 3.7% | ||
| Q2 25 | 2.4% | 3.5% | ||
| Q1 25 | 2.2% | 3.1% | ||
| Q4 24 | 9.4% | 3.3% | ||
| Q3 24 | 2.2% | 4.0% | ||
| Q2 24 | 2.9% | 3.9% | ||
| Q1 24 | 4.1% | 3.3% |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | -2.99× | ||
| Q2 25 | — | 2.98× | ||
| Q1 25 | — | 0.94× | ||
| Q4 24 | — | 1.66× | ||
| Q3 24 | — | -0.71× | ||
| Q2 24 | — | 2.83× | ||
| Q1 24 | — | 1.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
LOPE
Segment breakdown not available.
